Synthesis and Anti-Tumor Activity of Proanthocyanidins

Hidefumi Makabe*  

Graduate School of Agriculture, Sciences of Functional Foods, Shinshu University, 8304 Minami-minowa Kami-ina, Nagano, 399-4598, Japan

Recently proanthocyanidins have been paid much attention due to their significant biological activities and beneficial effects for health. Among the broad biological activities of proanthocyanidins, the author focused on the anti-tumor activity of proanthocyanidins including our work.

Since Konings and co-workers reported moderate cytotoxicity of proanthocyanidins to human tumour cell lines in 1994 [1], more than 50 papers have been reported. However, in most of cases, evaluation of antitumor activity was investigated using the mixture of proanthocyanidins such as “grape seeds extract”. Thus the numbers of report of systematic structural activity relationship study (SAR) of proanthocyanidins against tumor cell lines are still limited. To solve this problem, synthesis of proanthocyanidins is necessary to obtain pure sample [2-5]. In this report, the author wishes to introduce the examples of synthesis and antitumor activity of proanthocyanidins with systematic SAR studies.

First example of synthesis and antitumor activity of the proanthocyanidin is reported by Kozikowski and co-workers in 1999. They synthesized 3-O-galloyl-(2R,3R)-epicatechin-4[β,8-3-O-galloyl-(2R,3R)-epicatechin] and its antitumor activity against human breast cancer cell lines (Figure 1) [6].

In 2003, synthesis procyanidin oligomer was reported by Kozikowski et al. [7]. They synthesized epicatechin oligomers and each compound was separated by HPLC and isolated products were evaluated antitumor activity. They found that cytotoxic effects were associated with high degree level of oligomerization at the 100 µg/mL dose. No activity was observed for the epicatechin dimer, trimer and tetramer. They also reported that these results are based on the induction of cell cycle arrest in the G0/G1 phase (Scheme 1).

In 2013, the first synthesis of prodelphinidin B3 and C2 and their anti-tumor activity against human PC-3 prostate cancer cell lines was reported by Fujii et al. [8]. They achieved total synthesis of prodelphinidin B3 and C2 using Lewis acid-mediated equimolar condensation of a catechin and/or catechin-gallocatechin nucleophile. In addition to achievement of the total synthesis, they examined antitumor activities against PC-3 prostate cancer cells. Prodelphinidin B1, B2, and B4 showed significant cytotoxic activity with IC50 values below 50 µM. The potencies seemed to be a little bit stronger than those of epigallocatechin-gallate (EGCG) and prodelphinidin B3 (Figure 3).

In addition to the prodelphinidins, Suda et al. [9] synthesized dimericcatechin and epicatechingallate and evaluated their antitumor activity against human prostate cancer cell lines. The results of antitumor activities showed significant cytotoxic activity but weaker than EGCG and prodelphinidins. This finding suggests that esterified pyrogallol moiety shows weaker activity compared to the compounds such as prodelphinidins (Figure 4).

Until now, the important structural factors of proanthocyanidins which show significant antitumor activity are as follows: 1) High degree oligomers show potent activity; 2) Proanthocyanidins which possess pyrogallol moiety show significant activity.

Figure 1: The structure of 3-O-galloyl-(2R,3R)-epicatechin-4j,8-[3-O-galloyl-(2R,3R)-epicatechin].

Scheme 1: Synthesis of epicatechin oligomers.
Proanthocyanidins have been paid attention to the synthetic and biological researchers due to their unique structures and significant biological activities. Recent progress of the synthesis of proanthocyanidins made detailed biological studies possible. However, there is still much room to develop synthesis and biological activities especially for the highly polymerized proanthocyanidins. When synthetic methods of these complex molecules will be able to be developed, further useful biological activities and its mechanism of action will be disclosed.

References
1. Kolodziej H, Haberland C, Voordenbag HJ, Konings, AWT (1994) Moderate cytotoxicity of proanthocyanidins to human tumour cell lines. Phytotherapy Research 9: 410-415.
2. Ohmori K, Suzuki K (2012) Synthesis and Tactics for Oligomeric Proanthocyanidins. Current Org Chem 16: 566-577.
3. Oyama K, Yoshida K, Kondo T (2011) Recent Progress in the Synthesis of Flavonoids: From Monomers to Supra-Complex Molecules. Current Org Chem 15: 2567-2607.
4. Ferreira D, Coleman CM (2011) Towards the synthesis of proanthocyanidins: half a century of innovation. Planta Med 77: 1071-1085.
5. Makabe H (2013) Recent Syntheses of Proanthocyanidins. Heterocycles 87: 2225-2248.
6. Tückmantel W, Kozikowski AP, Romanczyk Jr LJ (1999) Studies in Polyphenol Chemistry and Bioactivity. 1. Preparation of Building Blocks from (+)-Catechin. Procyanidin Formation. Synthesis of the Cancer Cell Growth Inhibitor, 3-O-Galloyl-(2R,3R)-epicatechin-4?,8-3-O-galloyl-(2R,3R)-epicatechin]. J Am Chem Soc 121: 12073-12081.
7. Kozikowski AP, Tückmantel W, Böttcher G, Romanczyk Jr LJ (2003) Studies in Polyphenol Chemistry and Bioactivity. 4. Synthesis of Trimeric, Tetrameric, Pentamer, and Higher Oligomeric Epicatechin-Derived Procyanidins Having All-4b,8-Interflavan Connectivity and Their Inhibition of Cancer Cell Growth through Cell Cycle Arrest. J Org Chem 68: 1641-1658.
8. Fujii W, Toda K, Kawaguchi K, Kawahara SI, Katoh M, et al. (2013) Syntheses of prodelphinidin B3 and C2, and their antitumor activities through cell cycle arrest and caspase-3 activation. Tetrahedron 69: 3543-3550.
9. Fujii W, Toda K, Kawaguchi K, Kawahara S-I, Katoh M, Hattori Y, Fujii H, Makabe H (2013) Syntheses of prodelphinidin B1, B2 and B4 and their antitumor activities against human PC-3 prostate cancer cell lines. Tetrahedron Lett 54: 7188-7192.
10. Suda M, Katoh M, Toda K, Matsumoto K, Kawaguchi K, et al. (2013) Syntheses of procyanidin B2 and B3 gallate derivatives using equimolar condensation mediated by Yb(OTf)3 and their antitumor activities. Bioorg Med Chem Lett 23: 4935-4939.